Gestational thrombocytopenia among pregnant women in Lagos, Nigeria

Sarah Oluwatayo Ajibola, Akinsegun Akinbami1, Kabiru Rabiu2, Adeniyi Adewunmi2, Adedoyin Dosunmu1, Adediran Adewumi3, Bodunrin Osikomaiya4, Kamal Ismail1

INTRODUCTION
Platelets are non-nucleated cells derived from megakaryocytes in the bone marrow and normally live in the peripheral circulation for as long as 10 days. Platelets play a critical initiating role in the haemostatic system.1

Thrombocytopenia is second only to anaemia as the most common haematologic abnormality during pregnancy.2 Thrombocytopenia is classically defined as a platelet count of less than 150 × 10⁹/L.3,4 Counts from 100 to 150 × 10⁹/L are considered mildly depressed, 50 to 100 × 10⁹/L are moderately depressed and less than 50 × 10⁹/L are severely depressed.5

The overall incidence of thrombocytopenia in pregnancy is 8%, but when patients with obstetric or medical conditions are excluded, the incidence drops to 5.1%.2 Some causes are unique to pregnancy, whereas others can be serious medical conditions that have been previously undiagnosed. The most common cause is gestational thrombocytopenia,3 which accounts for almost three-fourths of all cases. Hypertensive disorders account for 21%.2 Thrombocytopenia occurs more commonly in patients with eclampsia (30%) than in patients with both mild and severe forms of preeclampsia (15-18%).2

Of the patients who have severe preeclampsia, 4-12% will manifest criteria for HELLP syndrome (haemolysis, elevated liver enzymes and low platelet counts).2 Immune-mediated thrombocytopenia, including idiopathic thrombocytopenic purpura and neonatal alloimmune...
thrombocytopenia, is responsible for 4.1% of cases, which is a proportionally small number. These conditions, however, can cause considerable morbidity and mortality and must be managed closely. Other, less common causes include rheumatologic disease (e.g. systemic lupus erythematosus), disseminated intravascular coagulation, thrombotic thrombocytopenia purpura, fatty liver, antiphospholipid syndrome, human immunodeficiency virus (HIV) infection and medications.

Gestational thrombocytopenia is a diagnosis of exclusion, use of automated blood counters in routine pre-natal screening has resulted in an increased diagnosis and the following five characteristics make it more likely: (1) the degree of thrombocytopenia is usually mild to moderate, usually remaining greater than 70 × 10^9/L (however, the lower level has never been established); (2) patients are asymptomatic with no history of bleeding; (3) there is no pre-conception history of thrombocytopenia; (4) an early gestation or preconception platelet count is normal and (5) the platelet count returns to normal within 2-12 weeks postpartum.

The cause of gestational thrombocytopenia is unclear, although it might be secondary to accelerated platelet consumption and the increased plasma volume associated with pregnancy. Anti-platelet antibodies have been detected in the serum, but this finding does not differentiate it from idiopathic thrombocytopenic purpura, and the presence of anti-platelet antibodies is not specific for gestational thrombocytopenia.

Gestational thrombocytopenia essentially poses no risk to either the mother or foetus-neonate. A prospective cohort study by Burrows and Kelton of 756 women with a diagnosis of gestational thrombocytopenia showed that none of the mothers and only 1 infant, which had congenital bone marrow dysfunction diagnosed later, had any bleeding complication. In another study by Nagey et al., of 730 pregnancies with platelet counts of less than 150 × 10^9/L, no neonate had a platelet count of less than 100 × 10^9/L and no bleeding complications were observed. Thus, it appears that mildly to moderately depressed platelet counts from gestational thrombocytopenia are not associated with any adverse effects to the foetus, neonate or mother, and no management is necessary other than periodic monitoring.

It is known that pregnant women with thrombocytopenia have a higher risk of bleeding excessively during or after childbirth, particularly if they need to have a caesarean section or other surgical intervention during pregnancy, labour or in the puerperium. Such bleeding complications are more likely when the platelet count is less than 50 × 10^9/L. Healthcare providers must weigh the benefits of interventions in relation to cost and morbidity against the risk of maternal and foetal bleeding complications.

This study was designed to determine the prevalence of gestational thrombocytopenia among pregnant women reporting for antenatal care at tertiary healthcare centres in Lagos.

**MATERIALS AND METHODS**

This was a cross-sectional study of 274 pregnant women attending the Lagos University Teaching Hospital (LUTH) and Lagos State University Teaching Hospital (LASUTH) antenatal clinics (situated at Orile Agege and Isolo general hospitals). During the study period between February and September 2012 all pregnant women who gave informed consent and satisfied the study inclusion criteria were recruited into the study. Thrombocytopenia is classically defined as a platelet count of less than 150 × 10^9/L. Counts from 100 to 150 × 10^9/L are considered mildly depressed, 50 to 100 × 10^9/L are moderately depressed and less than 50 × 10^9/L are severely depressed. Data collected from them was entered into a data sheet. All study participants were on routine ferrous sulphate tablet 200 mg three times daily, folic acid tablets 5 mg daily and vitamin B complex tablets three times daily.

The research was approved by the Ethics Review Committees of both LUTH and LASUTH.

**Inclusion criteria**

Among the pregnant women who gave informed consent, only those who had normotensive blood pressure less than or equal to 140/90 mmHg were recruited at various gestational ages.

**Exclusion criteria**

Pregnant women with the following conditions were excluded from the study: bleeding disorders, women on non-steroidal anti-inflammatory drugs such as aspirin, splenomegaly, connective tissue disease such as systemic lupus erythematosus (SLE), hypertension, HIV and hepatitis B infection. Information such as drug history, presence of splenomegaly and HIV/hepatitis B status were extracted from the clinical notes.

Sample size was estimated using the sample size expression:

\[ n = \frac{Z^2pq}{d^2} \]

Where \( n \) = the desired sample size.

\( Z \) = the standard normal deviation, usually set at 1.96, which correspond to the 95% confidence interval.

\( p \) = the proportion in the target population estimated to have a particular characteristic. In this case, a reasonable
estimate will be 0.15 (15.3%). This reasonable estimate will be chosen based on prevalence of 15.3% in the literature.\textsuperscript{11}

\[ Q = 1.0 - p = 1.0 - 0.15 = 0.85 \]

\[ D = \text{degree of accuracy, usually set at 0.05}. \]

\[ n = 196. \]

However, 274 participants were recruited.

Blood specimen was withdrawn with minimal stasis from the ante-cubital vein using a dry sterile disposable syringe and needle. Four and half millilitres of blood was collected and dispensed into ethylenediamine tetraacetic acid ethylenediamine tetraacetic acid (EDTA) anticoagulant tubes. The specimens were labelled with subject’s age, sex and identification number. The EDTA samples were kept at room temperature until processed within 4 hours of collection. Full blood count was performed using the Sysmex KN-21N, (manufactured by Sysmex corporation Kobe, Japan) a three-part auto analyzer able to run 19 parameters per sample including haemoglobin concentration, packed cell volume, red blood cell concentration and platelets. Standardization, calibration of instrument and processing of samples were done according to manufacturer’s instructions. Well mixed blood sample was aspirated, by letting the equipment sampling probe into the blood sample and then pressing the start button. Approximately 20 µl of blood was aspirated by the auto analyzer. Result of analysis is displayed after about 30 s. A printout copy of result is released on the thermal printing paper.

**Statistical analysis**

Data were analyzed using SPSS version 16.0 (Statistical Package for Social Sciences, Inc., Chicago, IL). The descriptive data were given as means ± standard deviation (SD). The Pearson chi-squared test was used for analytic assessment and the differences were considered to be statistically significant when the \( P \) value obtained was <0.05.

**RESULTS**

A total of 274 pregnant women and 70 non-pregnant controls were recruited. Thirty-seven (13.5%) pregnant women were thrombocytopenic, compared with three (4.3%) control subjects (\( P = 0.03 \); Odds ratio: 3.5 (95% confidence interval 1.0305-11.8225). Majority of the participants (183 of 274; 66.8%) were in their second trimester as at the time of the study, followed by third trimester participants (53 of 274; 19.3%) and first trimester patients (38 of 274; 13.9%).

The overall platelet mean was 228.29 ± 65.6 \( \times 10^9 \)L. A statistically significant relationship could not be established between platelet counts and various trimesters of pregnancy \( P = 0.998 \), neither could it be established between platelet counts and gestational age in weeks \( P = 0.296 \), nor between platelet counts and parity \( P = 0.992 \).

Figure 1 shows the distribution of thrombocytopenia among pregnant women at different trimesters. In the first trimester, 83.3% of pregnant women who were thrombocytopenic had mild thrombocytopenia, compared with 80% and 72.7% in the second and third trimesters, respectively. No pregnant woman in the first trimester had severe thrombocytopenia.

Figure 2 illustrates the severity of thrombocytopenia among pregnant women. Out of the 37 pregnant women who were thrombocytopenic, most of them (78%) had mild thrombocytopenia. However, all the thrombocytopenic control subjects had mild thrombocytopenia.

**DISCUSSION**

This work was designed to determine the prevalence of gestational thrombocytopenia in pregnant women attending antenatal care at tertiary health centres in Lagos. Significantly more pregnant women in this study...
were thrombocytopenic compared with non-pregnant healthy controls. Pregnant women were at least three times more likely to be thrombocytopenic compared with controls.

The prevalence of gestational thrombocytopenia in our study was 13.5%. This figure is similar to that of 15.3% reported by Edeghogho et al.,11 in Ghanaian pregnant women. However, it is higher than figures of 11.6% reported by Boehlen et al., in 200612 and 7.2% reported by Sainio et al., in 2000 in the Western world.13 The fact that in this study, majority of the pregnant women were in the second trimester could explain the higher prevalence.

From our findings, gestational thrombocytopenia occurred across the three trimesters, this was against the report of Crowther et al.,14 who reported that gestational thrombocytopenia in pregnancy is a disorder that develops primarily in the late second or third trimester. These observations suggest that pregnancy is associated with a mild and generally unappreciated decrease in the circulating platelet count.

Most of the cases of thrombocytopenia (78.4%) in our study were mild with platelet counts above 100 × 10^9/L; this agrees with the finding of Boehlen13 who reported that gestational thrombocytopenia is usually mild.

In accordance with previous studies on early versus late antenatal booking, this study reported a preponderance of the participants registered for antenatal clinic (ANC) in second trimester, followed by the third and only 13.87% of the participants registered early for ANC. This finding tallies with various studies from different regions in Nigeria, which reported that most pregnant women registered above 20 weeks.15-18

This study reported a decline in platelet count as pregnancy advances; this is also consistent with the study of Akingbola et al.19 Due to haemodilution secondary to expansion of plasma volume, platelet count in normal pregnancies may decrease by approximately 10%, most of this decrease occurs during the third trimester,20-22 though the absolute platelet count remains within normal reference range in most patients.3,4,21,22

The trimester-specific platelet counts obtained in this study also tallies with what Akingbola et al.,15 reported in Ibadan, Nigeria in 2006 but slightly higher than what Onwukeme et al.,23 reported in Jos, Nigeria in 1990.

It is obvious from various studies3,4,21,22 that majority of pregnant women still have levels within the normal range; however, if pre-pregnancy levels are border-line, or there is a more severe reduction, the level may fall below the normal range. The mechanisms for this are thought to be dilutional effects and accelerated destruction of platelets passing over the often scarred and damaged trophoblast surface of the placenta.24 Platelet counts may also be lower in women with twin compared with singleton pregnancies, possibly related to greater increase of thrombin generation.25 Although most cases of thrombocytopenia in pregnancy are mild, with no adverse outcome for mother or baby, occasionally a low platelet count may be part of a complex disorder with significant morbidity and may (rarely) be life-threatening.

Overall, about 75% of cases of thrombocytopenia in pregnancy are due to gestational thrombocytopenia; 15-20% secondary to hypertensive disorders; 3-4% due to an immune process and the remaining 1-2% made up of rare constitutional thrombocytopenias, infections and malignancies.4

CONCLUSION

Majority of pregnant women have platelet counts within the non-pregnant normal range, the prevalence of thrombocytopenia in this study was 13.5%. This rather high figure could be as a result of majority of the pregnant women being in the second trimester in the study.

Since gestational thrombocytopenia is usually mild or moderate, pregnant women found to have severe thrombocytopenia should be investigated to exclude other causes of thrombocytopenia in pregnancy such as autoimmune diseases and pre-eclampsia. Care should be taken during delivery of women with thrombocytopenia especially if severe to avoid bleeding complications.

REFERENCES

1. Vera EV. Thrombocytopenia in pregnancy. 2012. Available from: www.emedicine.medscape.com/article [Last accessed 2012 Oct 07].
2. Sullivan CA, Martin JN Jr. Management of the obstetric patient with thrombocytopenia. Clin Obstet Gynecol 1995;38:521-34.
3. Shehata N, Burrows R, Kelton JG. Gestational thrombocytopenia. Clin Obstet Gynecol 1999;42:327-34.
4. Burrows RF, Kelton JG. Thrombocytopenia at delivery: A prospective survey of 6,715 deliveries. Am J Obstet Gynecol 1990;162:731-4.
5. Magann EF, Martin JN Jr. Twelve steps to optimal management of HELLP syndrome. Clin Obstet Gynecol 1999;42:532-50.
6. Levy JA, Murphy LD. Thrombocytopenia in Pregnancy. J Am Board Fam Pract 2002;15:290-7.
7. Silver R, Berkowitz R, Bussel J. Thrombocytopenia in pregnancy. Practise bulletin, No 6. Chicago: American Society of Obstetrics and Gynaecology, 1999
8. Nagey DS, Alger LS, Edelmann BB, Heyman MR, Pupkin MU, Crenshaw C Jr. Reacting appropriately to thrombocytopenia in pregnancy. South Med J 1986;79:1385-8.
9. Richard F, Alexandre H. Thrombocytopenia in pregnancy. 2006. Available from: www.emedicine.medscape.com/article [Last accessed 2011 Jan 15].
10. Araoye MO. Subjects selection. In: Research methodology with statistics for health and social sciences. Nathadex Publishers, 2004:115-29.
11. Olayemi E, Akuffo FW. Gestational thrombocytopenia among pregnant Ghanaian women. Pan Afr Med J 2012;12:34.
12. Boehlen F, Hohlfeld P, Extermann P, Perneger TV, de Moerloose P. Platelet count at term pregnancy: A reappraisal of the threshold. Obstet Gynecol 2000;95:29-33.
13. Sainio S, Kekomäki R, Rikkonon S, Teramo K. Maternal thrombocytopenia at term: A population-based study. Acta Obstet Gynecol Scand 2000;79:744-9.
14. Crowther MA, Burrows RF, Ginsberg J, Kelton JG. Thrombocytopenia in pregnancy: Diagnosis, pathogenesis and management. Blood Rev 1996;10:8-16.
15. Ghororo EP, Igbafe AA. Antenatal care: Some characteristics of the booking visit in a major teaching hospital in developing world. Med Sci Monit 2000;6:519-22.
16. Adeyemi AB, Makinde ON, Ajenifuja KO, Soyinka AS, Ayinde AK, Ola BA, et al. Determinants of antenatal booking time in South-Western Nigeria setting. West Afr J Med 2007;26:293-7.
17. Okunola MA, Ayinde OA, Owonikoko KM, Omigbodun AO. Factors influencing gestational age at antenatal booking at the University college hospital Ibadan, Nigeria. J Obstet Gynaecol 2006;26:195-7.
18. Oladokun A, Oladokun RE, Mohanson-Bello I, Bello AF, Adeokun B. Proximate predictors of early antenatal registration among Nigerian pregnant women. Ann Afr Med 2010;9:222-5.
19. Akingbola TS, Adewole IF, Adesina OA, Afolabi KA, Fehintola FA, Bamgboye EA, et al. Haematological profile of healthy pregnant women in Ibadan, south-western Nigeria. J Obstet Gynaecol 2006;26:763-9.
20. McCrae KR. Thrombocytopenia in pregnancy: Differential diagnosis, pathogenesis, and management. Blood Rev 2003;17:7-14.
21. Ballem PJ. Hematological problems of pregnancy. Can Fam Physician 1988;34:2531-7.
22. Burrows RF, Kelton GJ. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993;329:1463-6.
23. Onwukeme KE, Uguru VE. Haematological values in pregnancy in Jos. West Afr J Med 1990;9:70-5.
24. Fay RA, Hughes AO, Farron NT. Platelets in pregnancy: Hyper destruction in pregnancy. Obstet Gynecol 1983;61:238.
25. Sunoda T, Ohkuchi A, Izumi A, Watanabe T, Matsubara S, Sato I. Minakami twin pregnancies than in singleton pregnancies. Acta Obstet Gynecol Scand 2002;81:840.

How to cite this article: Ajibola SO, Akinbami A, Rabiu K, Adewumi A, Dsonnu A, Adewumi A, et al. Gestational thrombocytopenia among pregnant women in Lagos, Nigeria. Niger Med J 2014;55:139-43. Source of Support: Nil, Conflict of Interest: None declared.